Cardiac Pathways FDA clearance:
This article was originally published in Clinica
Cardiac Pathways has received US FDA 510(K) clearance to begin marketing its RPM (real-time position management) tracking system. It is intended for use in most diagnostic electrophysiology procedures for real-time visualisation of catheters and is expected to assist physicians in precisely manipulating catheters within the heart during procedures, offering the potential for reductions in procedure times, the Sunnyvale, California-based company said.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.